FDA Approves Opdivo-Yervoy Combo for First-line Treatment of Advanced NSCLC

The U.S. Food and Drug Administration (FDA) has approved a combination of Opdivo (nivolumab) with low-dose Yervoy (ipilimumab) for the initial treatment of people with metastatic non-small cell lung cancer (NSCLC) whose tumors produce the PD-L1 protein. The approval is for those without alterations in the EGFR or ALK genes, and comes on the heels of promising findings from part 1a of the CheckMate-227 Phase 3 trial (NCT02477826), in which the double immunotherapy combo significantly extended survival…

You must be logged in to read/download the full post.